High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients

Autor: Kucuk A, Topkan E, Selek U, Haksoyler V, Mertsoylu H, Besen AA, Pehlivan B

Publikováno v: Therapeutics and Clinical Risk Management, Vol Volume 18, Pp 421-428 (2022)

Ahmet Kucuk,1 Erkan Topkan,2 Ugur Selek,3,4 Veysel Haksoyler,5 Huseyin Mertsoylu,6 Ali Ayberk Besen,6 Berrin Pehlivan7 1Clinic of Radiation Oncology, Mersin Education and Research Hospital, Mersin, Turkey; 2Department of Radiation Oncology, Baskent U

Externí odkaz: https://doaj.org/article/f9b51a46c59249ffb20c7533fa30daed

Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.

Autor: Takashima A; Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan., García-Alfonso P; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain., Manneh R; Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Beşen AA; Baskent University Medical Faculty, Department of Medical Oncology, Adana, Turkey., Hong YS; Asan Medical Center, University of Ulsan College of Medicine, Seoul, the Republic of Korea., Cuyle PJ; Gastroenterology and Digestive Oncology Department, Imelda General Hospital, Bonheiden, Belgium., Yanez P; Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile., Burge M; Royal Brisbane and Women's Hospital, Herston, QLD, Australia., Yoshino T; National Cancer Center Hospital East, Chiba, Japan., Kim TW; Asan Medical Center, University of Ulsan College of Medicine, Seoul, the Republic of Korea., Cui K; AstraZeneca, Gaithersburg, MD, USA., Li C; Merck & Co., Inc., Rahway, NJ, USA., Jain R; Merck & Co., Inc., Rahway, NJ, USA., Adelberg D; Merck & Co., Inc., Rahway, NJ, USA., Taieb J; Georges Pompidou European Hospital, SIRIC-CARPEM, Université Paris Cité, Paris, France. Electronic address: jtaieb75@gmail.com.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jul; Vol. 205, pp. 114036. Date of Electronic Publication: 2024 Mar 21.

Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?

Autor: Sümbül AT; Depertment of Medical Oncology, Mustafa Kemal University Medical Faculty, Hatay, Turkey., Dişel U; Depertment of Medical Oncology, Hatay Defne Hospital, Hatay, Turkey., Sezgin N; Depertment of Biochemistry, Başkent University Medical Faculty, Adana, Turkey., Sezer A; Depertment of Medical Oncology, Başkent University Medical Faculty, Adana, Turkey., Köse F; Medical Oncology, Başkent University Medical Faculty, Adana, Turkey., Beşen AA; Depertment of Medical Oncology, Başkent University Medical Faculty, Adana, Turkey., Sümbül Z; Depertment of Cardiology, Hatay Antakya State Hospital, Hatay, Turkey., Abalı H; Depertment of Medical Oncology, Başkent University Medical Faculty, Adana, Turkey., Özyılkan Ö; Depertment of Medical Oncology, Başkent University Medical Faculty, Adana, Turkey.

Publikováno v: Medical science monitor : international medical journal of experimental and clinical research [Med Sci Monit] 2014 Mar 15; Vol. 20, pp. 428-33. Date of Electronic Publication: 2014 Mar 15.

A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.

Autor: Dişel U, Beşen AA, Özyılkan Ö, Er E, Canpolat T

Publikováno v: Oral oncology [Oral Oncol] 2012 Feb; Vol. 48 (2), pp. e2-3. Date of Electronic Publication: 2011 Aug 23.